Antyhypertensive therapy-based secondary prevention of ischemic stroke
https://doi.org/10.14412/2074-2711-2012-370
Abstract
About the Authors
Vladimir Anatolyevich ParfenovDepartment of Nervous Diseases, Faculty of Therapeutics
S V Verbitskaya
Department of Nervous Diseases, Faculty of Therapeutics
Yu A Starchina
Department of Nervous Diseases, Faculty of Therapeutics
References
1. <div><p>Шевченко О.П., Праскурничий Е.А., Яхно Н.Н. и др. Артериальная гипертония и церебральный инсульт. М., 2001;192 с.</p><p>Суслина З.А., Гераскина Л.А., Фонякин А.В. Артериальная гипертония, сосудистая патология мозга и антигипертензивное лечение. М.: Медиаграфикс, 2006;200 с.</p><p>Sacco R.L., Adams R., Albers G. et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:577—617.</p><p>European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis 2008;25:457—507.</p><p>Суслина З.А., Фонякин А.В., Гераскина Л.А. и др. Практическая кардионеврология. М.: ИМА-ПРЕСС, 2010;304 с.</p><p>Furie K.L., Kasner S.E., Adams R.J. et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2011;42:227—76.</p><p>Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995;346:1647—53.</p><p>Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903—13.</p><p>Vasan R.S., Beiser A, Seshardi S. et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Stud. JAMA 2002;287:1003—10.</p><p>Chalmers J., MacMahon S., Anderson C. et al. Clinician's manual on blood pressure and stroke prevention. Second ed. London, 2000;129 p.</p><p>Rashid P., Leonardi-Bee J., Bath P.P. Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events. Stroke 2003;34:2741—8.</p><p>Zhang H., Thijs L., Staessen J.A. Blood Pressure Lowering for Primary and Secondary Prevention of Stroke. Hypertension 2006;48:187—95.</p><p>Lawes C.M.M., Bennett D.A., Feigin V.L. et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004;35:776—85.</p><p>Lakhan S.E., Sapko M.T. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med 2009;2:30.</p><p>Rothwell P.M., Howard S.C., Spence J.D. et al. Relationship between Blood Pressure and Stroke Risk in Patients With Symptomatic Carotid Occlusive Disease. Stroke 2003;34:2583—92.</p><p>The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993;24:543—8.</p><p>Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med J 1995;108:710—7.</p><p>Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145—53.</p><p>Svensson P., de Faire U., Sleight P. et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001;38:e28-e32.</p><p>PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient schaemic attack. Lancet 2001;358:1033—41.</p><p>Schrader J., Luders S., Kulschewski A. et al. Mortality and morbidity after stroke, Eprosartan compared with Nitrendipine for secondary prevention. Principal results of a prospective randomised controlled study (MOSES). Stroke 2005;36:1218—26.</p><p>Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N Engl J Med 2008;359:1225-37.</p><p>De la Sierra A. Effects of eprosartan on target organ protection. Vasc Health Risk Manag 2006;2:79-85.</p><p>Schrader J., Kulschewski A., Dendorfer A. Inhibition of the renin-angiotensin system and the prevention of stroke. Am J Cardiovasc Drugs 2007;7:25-37.</p><p>Парфенов В.А., Старчина Ю.А., Яхно Н.Н. Эпросартан (теветен) в профилактике повторного инсульта и когнитивных нарушений. Неврол журн 2007;1:46—51.</p><p>Schwander B., Gradl B., Zöllner Y. et al. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe — the HEALTH model. Value Health 2009;12:857-71.</p><p>Парфенов В.А., Рыжак А.А. Неврологические аспекты оптимизации антигипертензивной терапии. Неврол журн 2003;2:26—9.</p><p>Вербицкая С.В., Парфенов В.А. Вторичная профилактика инсульта в амбулаторных условиях. Неврол журн 2011;1:17—21.</p></div><br />
Review
For citations:
Parfenov VA, Verbitskaya SV, Starchina YA. Antyhypertensive therapy-based secondary prevention of ischemic stroke. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(1):96-101. (In Russ.) https://doi.org/10.14412/2074-2711-2012-370